All Videos

Guardrails and disclaimers are essential for responsible AI deployment in dermatology, according to Faranak Kamangar, MD.

Who is a woman who has shaped your life and career in dermatology? Hear stories from our experts as we celebrate Women's History Month 2026.

Linda Stein Gold, MD, FAAD, shares her thoughts on FDA-approved, once-daily oral icotrokinra for teens and adults with moderate to severe plaque psoriasis, promising biologic-like results, strong safety, and earlier systemic escalation.

PANP360 Immersive will deliver one-day, high-yield dermatology CME for NPs and PAs, featuring hands-on workshops, complex case strategies, and practical tips to optimize therapies.

Explore innovative strategies for treating psoriasis, emphasizing patient communication and evolving treatment goals for better outcomes.

Dermatologists weigh rifamylast, JAK inhibitors and antifungals for long-term seborrheic dermatitis control, balancing efficacy, safety and access.

New rifamilast 0.3% foam shows fast, sustained seborrheic dermatitis clearing with high tolerability—plus tips for long-term maintenance.

Healthcare professionals discuss the balance between patient satisfaction and clinical goals, emphasizing the importance of individualized treatment approaches.

Only 15–20% of eligible patients currently receive systemic psoriasis treatment, and specialists believe icotrokinra's simplicity could meaningfully move that needle.

Dr. Madigan highlights the evolving treatment landscape by discussing promising clinical trial data for second-generation KIT inhibitors, like bezaclastinib and elenestinib, which offer high selectivity and limited CNS penetration. She reinforces the "practice pearl" that nearly all adults with fixed skin lesions have systemic disease, emphasizing that these lesions are distinct from transient hives and require lifelong vigilance.

When used thoughtfully, Faranak Kamangar, MD, says AI can transform generic processes into innovative, time-saving clinical tools.

In this episode, the expert dermatologists explore the quality-of-life outcomes from the STOP HS trials, emphasizing that for patients, the biggest wins are often less pain and less drainage, outcomes not fully captured by HiSCR.

Learn why hidradenitis suppurativa is often mistaken for infection and who it affects—key myths that delay diagnosis and proper care.

Learn why hidradenitis suppurativa isn’t an infection, isn’t caused by poor hygiene, and can affect anyone—key myths delaying diagnosis.

This episode features panelists moving beyond HiSCR50 to examine the “depth of response” endpoints—HiSCR75, HiSCR90, and HiSCR100—and what they mean clinically.

Discover how rifamylast foam, a new FDA-approved PDE4 inhibitor, offers steroid-free relief for seborrheic dermatitis—calms itch, face-safe.

Discover how FDA-approved rifamylast foam targets PDE4 to calm seborrheic dermatitis—face-safe, steroid-free relief for itch and redness.

Explore effective strategies for managing poorly controlled psoriasis, focusing on systemic treatments and patient-centered care for optimal outcomes.

Explore the importance of multidisciplinary care in rheumatology, emphasizing collaboration among specialists for optimal patient outcomes.

Mark Lebwohl, MD, reviews how the AdvanceAD-Tx 487-GEP test identifies which patients are likely to need a JAK inhibitor rather than a biologic.

Dr. Madigan presents the case of a 50-year-old woman with refractory indolent systemic mastocytosis whose severe gastrointestinal and cutaneous symptoms persisted despite a high medication burden of antihistamines, cromolyn sodium, and oral steroids.

On National Skin Barrier Day, dermatologists share barrier-saving tips for gentle cleansing, daily sunscreen, smarter product audits, and retinoid adherence.

Compared with topical regimens, Rossi notes PDT provides a shorter recovery window and fewer adherence challenges.

This episode examines the persistent barriers that contribute to the delayed diagnosis of hidradenitis suppurativa, highlighting the need for greater disease awareness, proactive screening by frontline providers, and the growing role of patient self-advocacy in improving earlier detection.

This episode explores the multidimensional burden of hidradenitis suppurativa, highlighting its physical, emotional, and economic impacts on patients while emphasizing the importance of compassionate care and improved disease recognition.

In this episode, our experts delve into the primary efficacy results of the STOP HS trials, focusing on HiSCR50 at weeks 12 and 24 and how to interpret those numbers.

In this episode, the panelists explore the baseline characteristics of the STOP HS trials and why they matter for interpreting the results and applying them to practice. They first emphasize the achievement of running a >1,200‑patient, global phase 3 HS program, urging clinicians everywhere to refer patients to clinical trials to keep building robust data.

Mark Lebwohl, MD, discusses how the 487-GEP test may help clinicians identify the most appropriate systemic therapy for patients with AD earlier in the treatment journey.

Red light–activated photodynamic therapy offers an effective field-based option for treating both visible and subclinical actinic keratoses.

Dylan Timmermann, PA-C, reflects on the experiences that shaped his career trajectory in dermatology and offers insights relevant to physician assistants and nurse practitioners entering the specialty.